AU2021237981A1 - Compositions for treating respiratory tract infection and uses thereof - Google Patents

Compositions for treating respiratory tract infection and uses thereof Download PDF

Info

Publication number
AU2021237981A1
AU2021237981A1 AU2021237981A AU2021237981A AU2021237981A1 AU 2021237981 A1 AU2021237981 A1 AU 2021237981A1 AU 2021237981 A AU2021237981 A AU 2021237981A AU 2021237981 A AU2021237981 A AU 2021237981A AU 2021237981 A1 AU2021237981 A1 AU 2021237981A1
Authority
AU
Australia
Prior art keywords
seq
peptide
group
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021237981A
Other languages
English (en)
Inventor
Andrew GEARING
David KENLEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lateral IP Pty Ltd
Original Assignee
Lateral IP Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900807A external-priority patent/AU2020900807A0/en
Application filed by Lateral IP Pty Ltd filed Critical Lateral IP Pty Ltd
Publication of AU2021237981A1 publication Critical patent/AU2021237981A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57554—Prolactin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2021237981A 2020-03-16 2021-03-16 Compositions for treating respiratory tract infection and uses thereof Abandoned AU2021237981A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2020900807 2020-03-16
AU2020900807A AU2020900807A0 (en) 2020-03-16 Compositions for treating respiratory tract infection and uses thereof
AU2020900818 2020-03-17
AU2020900818A AU2020900818A0 (en) 2020-03-17 Compositions for treating respiratory tract infection and uses thereof
AU2020904226 2020-11-16
AU2020904226A AU2020904226A0 (en) 2020-11-16 Compositions for treating respiratory tract infection and uses thereof
PCT/AU2021/050229 WO2021184062A1 (en) 2020-03-16 2021-03-16 Compositions for treating respiratory tract infection and uses thereof

Publications (1)

Publication Number Publication Date
AU2021237981A1 true AU2021237981A1 (en) 2022-10-13

Family

ID=77767913

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021237981A Abandoned AU2021237981A1 (en) 2020-03-16 2021-03-16 Compositions for treating respiratory tract infection and uses thereof

Country Status (7)

Country Link
US (1) US20230256059A1 (https=)
EP (1) EP4121084A4 (https=)
JP (1) JP2023518376A (https=)
CN (1) CN115297882A (https=)
AU (1) AU2021237981A1 (https=)
CA (1) CA3171917A1 (https=)
WO (1) WO2021184062A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021003531A1 (en) * 2019-07-09 2021-01-14 Lateral IP Pty Ltd Peptides and uses thereof
JP2024516327A (ja) * 2021-05-07 2024-04-12 ラテラル、ファーマ、プロプライエタリー、リミテッド 炎症性気道疾患を処置するための組成物及びその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20080333A0 (fi) * 2008-05-02 2008-05-02 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
BR112014013757A2 (pt) * 2011-12-09 2019-08-27 Metabolic Pharmaceuticals Pty Ltd método para tratar osteoartrite; método para tratar uma condição que envolve condrócitos funcionais insuficientes ou tecido cartilaginoso funcional insuficiente; e uso de um peptídeo
US9139626B2 (en) * 2012-09-13 2015-09-22 The Mitre Corporation Mitrecin A polypeptide with antimicrobial activity
SG11202006669RA (en) * 2018-01-15 2020-08-28 Lateral IP Pty Ltd Peptides and uses thereof
KR20220124196A (ko) * 2019-12-27 2022-09-13 레터럴 아이피 피티와이 리미티드 사이클릭 펩티드 수용체 란티오닌 신테타제 c-유사 단백질 (lancl) 및 이의 용도

Also Published As

Publication number Publication date
JP2023518376A (ja) 2023-05-01
CN115297882A (zh) 2022-11-04
EP4121084A4 (en) 2024-04-03
WO2021184062A1 (en) 2021-09-23
CA3171917A1 (en) 2021-09-23
US20230256059A1 (en) 2023-08-17
EP4121084A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
ES3055494T3 (en) Treatment of respiratory diseases
AU2021237981A1 (en) Compositions for treating respiratory tract infection and uses thereof
US20220160815A1 (en) Peptides and uses thereof
CA2817787C (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
US9149514B2 (en) Composition and method for treating papilloma virus and equine sarcoids
WO2023165566A1 (zh) 治疗、预防由病毒感染引起的相关疾病的药物及其用途
US20250263435A1 (en) Peptide compositions capable of binding lanthionine synthetase c-like protein (lancl) and uses thereof
CN102716105A (zh) 干扰素α的干粉吸入剂
US20250255934A1 (en) Compositions for treating inflammatory airway disease and uses thereof
US7132453B2 (en) Method of using prostacyclin to treat respiratory syncytial virus infections
WO2021253647A1 (zh) 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
US12492223B2 (en) Peptide compositions capable of binding lanthionine synthetase C-like protein (LanCl) and uses thereof
US20240101629A1 (en) Use of interleukin-7 for the treatment of coronavirus
KR20070012522A (ko) 면역조절제 화합물로의 호흡기 바이러스 감염의 치료 및예방
CN108926707A (zh) Pf4的抗rsv应用
WO2021204985A1 (en) Use of vidofludimus for the treatment of coronavirus infections
WO2021228875A1 (en) Treatment of respiratory viral infections
CA3167593A1 (en) Method and drug for treating viral pneumonia
RU2678981C2 (ru) Композиция от бешенства, содержащая адъювант pika
WO2025129029A2 (en) Combinations of foralumab with glucagon-like peptide 1 (glp-1) agonists or sodium-glucose cotransporter-2 (sglt2) inhibitors and methods of use thereof
WO2006095433A1 (ja) ウシの消化器疾患治療剤
WO2021188854A1 (en) Ribonucleases for treating viral infections
WO2022109465A1 (en) Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus
HK40082469A (en) Hybrid interferons for treating viral infections
HK40082469B (en) Hybrid interferons for treating viral infections

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application